Insider Buying: AgomAb Therapeutics (NASDAQ:AGMB) Director Buys $43,500.00 in Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) Director David Epstein acquired 5,000 shares of the stock in a transaction on Tuesday, October 6th. The stock was purchased at an average cost of $8.70 per share, with a total value of $43,500.00. Following the transaction, the director directly owned 10,000 shares of the company’s stock, valued at $87,000. This represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

AgomAb Therapeutics Price Performance

NASDAQ AGMB opened at $9.08 on Friday. The company’s fifty day simple moving average is $12.60 and its 200-day simple moving average is $11.93. AgomAb Therapeutics NV has a 52 week low of $7.97 and a 52 week high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. On average, equities research analysts expect that AgomAb Therapeutics NV will post -1.76 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on AGMB shares. Cantor Fitzgerald assumed coverage on AgomAb Therapeutics in a research note on Wednesday, August 19th. They issued an “overweight” rating on the stock. Piper Sandler began coverage on AgomAb Therapeutics in a report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price objective on the stock. Wall Street Zen lowered AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. B. Riley Financial began coverage on shares of AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a report on Wednesday, September 16th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, AgomAb Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.50.

About AgomAb Therapeutics

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.